Clinical trial
Study of ZIO-101 in Multiple Myeloma
NCT00303199 · Alaunos Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00303199 |
|---|---|
| Title | Study of ZIO-101 in Multiple Myeloma |
| Official title | A Phase I/II Trial of ZIO-101 in Advanced Multiple Myeloma |
| Lead sponsor | Alaunos Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | ZIO-101 (Darinaparsin) |
| Enrollment | 35 |
| Start date | Jan 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Mar 15, 2006 |
| Last update posted | Jul 19, 2012 |
| Countries | Canada, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: